Skip to main content
. 2014 Jul 11;4(7):e226. doi: 10.1038/bcj.2014.47

Figure 2.

Figure 2

Kaplan–Meier survival curves showing EFS and OS from the time of diagnosis according to CEBPA mutation status. (a) EFS and (b) OS of patients harboring CEBPA mutations, patients harboring WT CEBPA (excluding core-binding factor-acute myeloid leukemia (CBF-AML) cases (WT non-CBF)) and patients with CBF-AML. (c) EFS and (d) OS of patients harboring a single CEBPA mutation (CEBPA-single), patients harboring double or triple CEBPA mutations (CEBPA-double), WT patients (excluding CBF-AML cases (WT non-CBF)) and patients with CBF-AML. P-values were determined using the log-rank test.